STOCK TITAN

Larimar Therapeutics (LRMR) Financials

LRMR NASDAQ
FY2025 annual
Revenue Not reported for FY2025
Net Income -$165.7M n/m YoY
Free Cash Flow -$113.3M n/m YoY
Operating Cash Flow -$113.2M n/m YoY
Market Cap $328.6M as of Nov 20, 2026
Price / Sales n/m no full year of revenue reported yet
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 3.2x on $101.5M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 16, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LRMR SEC filings page.

This page shows Larimar Therapeutics, Inc. (LRMR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LRMR FY2025

Larimar’s finances show a research-led development business where escalating spending is consuming cash and weakening the equity cushion.

FY2025’s operating cash flow of -$113M nearly matched free cash flow, showing little cash leakage outside operations. With capital expenditures at only $91K, the shortfall was driven by research activity rather than physical expansion.

Research and development rose to $154M from $73M in FY2024, making research the central use of operating resources. Operating loss widened to $172M from $90.9M, so the larger program was not yet accompanied by operating self-funding.

The balance sheet shifted toward creditor claims: liabilities reached $67.8M while equity fell to $78.1M in FY2025. A current ratio of 2.2x and reported liquidity equal to 14.5 months of latest annual operating outflow indicate short-term resources still exceeded near-term obligations.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Larimar Therapeutics, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
1/6

Larimar Therapeutics, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing
N/A

Larimar Therapeutics, Inc. reported a net loss of $165.7M while operations used $113.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA
-$32.4M
YoYn/m
QoQn/m
5Y CAGRn/m

Larimar Therapeutics, Inc.'s EBITDA was -$32.4M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$31.1M
YoYn/m
QoQn/m
5Y CAGRn/m

Larimar Therapeutics, Inc. reported a net loss of $31.1M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q3 2026.

EPS (Diluted)

Not reported for Q3 2026.

Cash & Balance Sheet

Free Cash Flow
-$31.2M
YoYn/m

Larimar Therapeutics, Inc. recorded an outflow of $31.2M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Cash & Debt
$77.0M
YoY-14.6%
QoQ-16.9%
5Y CAGR+1.5%

Larimar Therapeutics, Inc. held $77.0M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
105M
YoY+22.3%
QoQ+0.7%

Larimar Therapeutics, Inc. had 105M shares outstanding in Q3 2026. This represents an increase of 22.3% from the same quarter a year earlier. Against the prior quarter it is up 0.7%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-30.7%
YoY+3.6pp
QoQ-4.9pp
5Y change-7.4pp

Larimar Therapeutics, Inc.'s quarterly ROE was -30.7% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 3.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.9 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$25.9M
YoY-42.3%
QoQ-7.4%
5Y CAGR+13.1%

Larimar Therapeutics, Inc. invested $25.9M in research and development in Q3 2026. This represents a decrease of 42.3% from the same quarter a year earlier. Against the prior quarter it is down 7.4%.

Capital Expenditures
$28K
YoY+21.7%

Larimar Therapeutics, Inc. invested $28K in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 21.7% from the same quarter a year earlier.

Share Buybacks

Not reported for Q3 2026.

LRMR Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LRMR quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
R&D Expenses$25.9M-42.3%$28.0M+19.8%$25.0M-5.7%$59.4M+122.1%$44.9M+222.8%$23.4M+18.7%$26.6M+105.2%$26.7M+151.1%
SG&A Expenses$6.5M+43.1%$6.4M+43.6%$6.1M+31.3%$4.6M+2.0%$4.6M+5.1%$4.4M-10.0%$4.6M+22.2%$4.6M+29.6%
Operating Income-$32.5Mn/m-$34.4Mn/m-$31.1Mn/m-$64.0Mn/m-$49.5Mn/m-$27.8Mn/m-$31.2Mn/m-$31.3Mn/m
EBITDA-$32.4Mn/m-$34.3Mn/m-$31.1Mn/m-$63.9Mn/m-$49.4Mn/m-$27.7Mn/m-$31.1Mn/m-$31.2Mn/m
Income TaxN/AN/AN/AN/A$0n/m$0n/mN/AN/A
Net Income-$31.1Mn/m-$32.8Mn/m-$29.6Mn/m-$62.5Mn/m-$47.7Mn/m-$26.2Mn/m-$29.3Mn/m-$28.8Mn/m
EPS (Basic)N/AN/AN/AN/A-$0.61n/m-$0.41n/m-$0.46n/m-$0.46n/m
EPS (Diluted)N/AN/AN/AN/A-$0.61n/m-$0.41n/m-$0.46n/m-$0.46n/m
Diluted Shares (Avg)N/AN/AN/AN/A78M+22.8%64M+0.4%64M+19.4%N/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.

LRMR Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LRMR quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'25FilingQ4'2410-K
Total Assets$140.5M-25.0%$165.3M+10.2%$208.5M+22.5%$145.8M-27.2%$187.3M-14.5%$150.0M-36.8%$170.2M-31.4%$200.2M+108.7%
Current Assets$136.2M-25.7%$160.7M+10.4%$205.0M+23.9%$142.0M-27.3%$183.2M-14.1%$145.6M-37.0%$165.5M-28.3%$195.3M+116.6%
Cash & Equivalents$77.0M-14.6%$92.7M+350.2%$177.9M+742.2%$85.4M+157.1%$90.1M+157.1%$20.6M-36.3%$21.1M-80.8%$33.2M+24.2%
Short-Term Investments$51.7M-39.4%$63.6M-46.1%$22.5M-83.5%$51.4M-65.8%$85.3M-49.4%$117.9M-39.1%$136.4M+16.4%$150.2M+150.2%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0-100.0%$0n/m
Total Liabilities$39.0M-19.2%$37.9M+25.8%$50.5M+94.9%$67.8M+138.5%$48.3M+134.3%$30.1M+17.0%$25.9M+49.2%$28.4M+99.9%
Current Liabilities$35.6M-21.0%$34.2M+28.2%$47.8M+115.8%$64.8M+166.0%$45.1M+177.0%$26.6M+26.0%$22.1M+72.4%$24.4M+156.2%
Non-Current Liabilities$3.4M+6.2%$3.8M+7.7%$2.7M-27.8%$3.0M-27.0%$3.2M-26.3%$3.5M-24.3%$3.8M-16.6%$4.1M-13.8%
Total Equity$101.5M-27.0%$127.4M+6.3%$158.0M+9.5%$78.1M-54.6%$139.0M-29.9%$119.9M-43.3%$144.3M-37.5%$171.8M+110.2%
Retained Earnings-$528.4Mn/m-$497.2Mn/m-$464.4Mn/m-$434.8Mn/m-$372.3Mn/m-$324.6Mn/m-$298.4Mn/m-$269.2Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

LRMR Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LRMR quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$31.2Mn/m-$44.0Mn/m-$44.6Mn/m-$38.5Mn/m-$28.8Mn/m-$19.4Mn/m-$26.5Mn/m-$21.8Mn/m
Depreciation & Amortization$57K-35.2%$62K-28.7%$64K-27.3%$87K+13.0%$88K+18.9%$87K0.0%$88K+10.0%$77K-4.9%
Stock-Based Compensation$2.2M+21.8%$2.1M+17.6%$2.0M+7.9%N/A$1.8M-8.8%$1.8M-20.6%$1.8M-13.8%N/A
Capital Expenditures$28K+21.7%N/AN/A$0-100.0%$23K-62.9%$19K$49K$179K
Free Cash Flow-$31.2Mn/mN/AN/A-$38.5Mn/m-$28.8Mn/m-$19.4M-$26.6M-$22.0M
Investing Cash Flow$12.4M-62.3%-$40.9M-317.1%$29.0M+100.7%$34.0M+77.1%$33.0M+21.1%$18.8Mn/m$14.4Mn/m$19.2Mn/m
Financing Cash Flow$3.1M-$435K$108.1M-$201K-658.3%N/AN/AN/A$36Kn/m

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

LRMR Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LRMR quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Return on Equity-30.7%+3.6pp-25.7%-3.9pp-18.7%+1.6pp-80.0%-63.3pp-34.3%-26.5pp-21.8%-11.6pp-20.3%-14.0pp-16.8%-0.9pp
Return on Assets-22.2%+3.3pp-19.8%-2.4pp-14.2%+3.0pp-42.9%-28.4pp-25.5%-18.4pp-17.5%-8.3pp-17.2%-11.3pp-14.4%-0.9pp
Current Ratio3.82-0.2x4.70-0.8x4.29-3.2x2.19-5.8x4.06-9.0x5.46-5.5x7.48-10.5x8.02-1.5x
Liabilities-to-Equity0.380.0x0.300.0x0.32+0.1x0.87+0.7x0.35+0.2x0.25+0.1x0.18+0.1x0.170.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Larimar Therapeutics, Inc. LRMR FY2025 N/A -$165.7M N/A $328.6M —
C4 Therapeutics, Inc. CCCC FY2025 $35.9M -$105.0M N/A $325.7M 66/100
Contineum Therapeutics, Inc. CTNM FY2025 N/A -$60.0M N/A $340.8M —
Inovio Pharmaceuticals, Inc. INO FY2025 $65K -$84.9M N/A $329.7M —
Opus Genetics, Inc. IRD FY2025 $14.2M -$49.6M N/A $385.7M 39/100
PepGen Inc. PEPG FY2025 N/A -$89.7M N/A $356.3M —

Frequently Asked Questions

No, Larimar Therapeutics, Inc. (LRMR) reported a net loss of $165.7M in fiscal year 2025.

Larimar Therapeutics, Inc. (LRMR) had EBITDA of -$172.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Larimar Therapeutics, Inc. (LRMR) has a return on equity of -212.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Larimar Therapeutics, Inc. (LRMR) recorded an outflow of $113.3M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Larimar Therapeutics, Inc. (LRMR) recorded an outflow of $113.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Larimar Therapeutics, Inc. (LRMR) had $145.8M in total assets as of fiscal year 2025, including both current and long-term assets.

Larimar Therapeutics, Inc. (LRMR) invested $91K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Larimar Therapeutics, Inc. (LRMR) invested $154.2M in research and development during fiscal year 2025.

Larimar Therapeutics, Inc. (LRMR) had 104M shares outstanding as of fiscal year 2025.

Larimar Therapeutics, Inc. (LRMR) had a current ratio of 2.19 as of fiscal year 2025, which is generally considered healthy.

Larimar Therapeutics, Inc. (LRMR) had a liabilities-to-equity ratio of 0.87 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Larimar Therapeutics, Inc. (LRMR) had a return on assets of -113.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Larimar Therapeutics, Inc. (LRMR) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $328.6M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Larimar Therapeutics, Inc. (LRMR) has no price-to-sales ratio at the moment: no full year of revenue reported yet. The market capitalization is $328.6M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Larimar Therapeutics, Inc. (LRMR) held $136.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $113.2M over that year. Dividing the one by the other, the reported balance equals about 15 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Larimar Therapeutics, Inc. (LRMR) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Larimar Therapeutics, Inc. (LRMR) reported a net loss of $165.7M while operations used $113.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top